Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Tapering of Immunosuppressive Agents in Advanced AML
NCT03150134Phase 4Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2010
- Primary completion
- Jan 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cyclosporine in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Relapse Free Survival at 2 years. Status: unknown.
02
Drugs
cyclosporine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03150134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150134.